Table 2. MYBL2 deregulation associated with patient outcome in different cancer entities.

Tumor entity	MYBL2 deregulation	Association with patient survival	References
Acute myeloid leukemia	Overexpression	MYBL2 expression is an independent prognostic factor for disease-free survival and cumulative incidence of relapse	Fuster et al.17
Bladder carcinoma	Overexpression (amplification)	Overrepresentation of amplicons in high-grade and recurrent cases	Nord et al.87
Breast cancer	Overexpression	Overexpression is associated with short overall patient survival and short disease-free survival	Inoue and Fry88
Colorectal cancer	Overexpression	Overexpression is correlated with worse disease-free survival and MYBL2 is an independent prognostic factor for poor patient survival	Ren et al.89
Esophageal squamous cell carcinoma	Overexpression (amplification)	High MYBL2 expression and high MYBL2 copy-number are associated with poor patient survival	Qin et al.90
Hepatocellular carcinoma	Overexpression, high phosphorylation levels	High levels of total and phosphorylated MYBL2 and high levels of LIN9–MYBL2 complex in HCC with poorer outcome	Calvisi et al.91
Neuroblastoma	Overexpression	MYBL2 expression is associated with increased risk of death and worse overall survival	Raschellà et al.92
Renal cell carcinoma	Positivity	Positivity for MYBL2 expression is significantly correlated with clinical stage III and IV	Sakai et al.93